Edwards Lifesciences (NYSE:EW) Stock Rating Upgraded by Wolfe Research

Edwards Lifesciences (NYSE:EW) was upgraded by stock analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Wednesday,Finviz reports. The brokerage presently has a $92.00 price target on the medical research company’s stock. Wolfe Research’s target price would suggest a potential upside of 14.91% from the stock’s current price.

EW has been the subject of a number of other research reports. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Evercore restated an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Wells Fargo & Company increased their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Finally, Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Trading Up 0.7%

Shares of EW opened at $80.07 on Wednesday. Edwards Lifesciences has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a market capitalization of $46.16 billion, a PE ratio of 43.75, a price-to-earnings-growth ratio of 2.07 and a beta of 0.93. The stock has a fifty day moving average of $81.85 and a two-hundred day moving average of $81.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, analysts forecast that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the sale, the vice president directly owned 33,934 shares in the company, valued at $2,897,284.92. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,827,387.38. This represents a 34.78% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 61,718 shares of company stock valued at $5,236,281. 0.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in the stock. Level Four Advisory Services LLC lifted its stake in shares of Edwards Lifesciences by 3.7% during the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after purchasing an additional 119 shares in the last quarter. Colonial Trust Co SC grew its stake in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after buying an additional 120 shares in the last quarter. Evermay Wealth Management LLC raised its holdings in shares of Edwards Lifesciences by 4.0% during the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after buying an additional 128 shares during the period. Rehmann Capital Advisory Group raised its holdings in shares of Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after buying an additional 130 shares during the period. Finally, Howard Capital Management Inc. lifted its position in Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after acquiring an additional 132 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.